Evidence map›Paper›PMID 36346710›Full record

ArticleThe Journal of antimicrobial chemotherapy2022

The effect of duration of therapy for treatment of Staphylococcus aureus blood stream infection: an application of cloning to deal with immortal-time bias in an analysis of data from a cohort study (BSI-FOO).

Rebecca N Evans, Jessica Harris, Chris A Rogers, Alasdair P Macgowan

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Short-termTherapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rebecca N EvansBristol Trials Centre, Bristol Medical School, University of Bristol, 1-5 Whiteladies Road, Clifton, BS8 1NU, Bristol, UK.ORCID 0000-0002-7119-8187
Jessica HarrisBristol Trials Centre, Bristol Medical School, University of Bristol, 1-5 Whiteladies Road, Clifton, BS8 1NU, Bristol, UK.
Chris A RogersBristol Trials Centre, Bristol Medical School, University of Bristol, 1-5 Whiteladies Road, Clifton, BS8 1NU, Bristol, UK.
Alasdair P MacgowanBristol Centre for Antimicrobial Research & Evaluation (BCARE), Infection Sciences, Pathology, North Bristol NHS Trust, Bristol, UK.
University of Bristol · GBNorth Bristol NHS Trust · GB

Funding

Department of Health RP-PG-0707-10043
6 · The paper itself

Abstract

objectiveTo estimate the effect of treatment duration on in-hospital mortality in patients with Staphylococcus aureus blood stream infection and demonstrate the biases that can arise when immortal-time bias is ignored. EXPOSURE: We compared three treatment strategies: short therapy (<10 days), intermediate (10-18 days) and long (>18 days).

main outcome measuresTwenty-eight-day all-cause in-hospital mortality.

methodsUsing data from the BSI-FOO study, we implemented an approach proposed by Hernán to overcome confounding and immortal-time biases. The first stage is to clone all participants, so that each participant is assigned to each treatment strategy. Second, observations are censored when their data becomes inconsistent with their assigned strategy. Finally, inverse-probability weights are applied to adjust for potential selection. We compared our results to a naïve approach where immortal-time bias is ignored.

resultsOf the 1903 participants in BSI-FOO, 587 were eligible and included in the analysis. After cloning, the weighted estimates of hazard ratio of mortality for short versus long therapy was 1.74 (95% CI 1.36, 2.24) and for intermediate versus long therapy was 1.09 (0.98, 1.22). In the naïve approach, the hazard ratios with reference to the long therapy group are 37.4 (95% CI 18.9 to 74.4) in the short therapy group and 4.1 (95% CI 1.9 to 8.9) in the intermediate therapy group.

conclusionsOur findings suggest that duration of therapy >18 days is beneficial with respect to 28-day in-hospital mortality, however, there remains uncertainty around the efficacy of reducing duration of treatment to 10-18 days.

Indexed as

Staphylococcal InfectionsStaphylococcus aureusBiasCloning, MolecularCohort StudiesDuration of TherapyHumans

Identifiers

PMID36346710
PMCPMC9780533
OpenAlexW4308527057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.